[go: up one dir, main page]

WO1999051625A3 - Peptides causing formation of compact structures - Google Patents

Peptides causing formation of compact structures Download PDF

Info

Publication number
WO1999051625A3
WO1999051625A3 PCT/US1999/007374 US9907374W WO9951625A3 WO 1999051625 A3 WO1999051625 A3 WO 1999051625A3 US 9907374 W US9907374 W US 9907374W WO 9951625 A3 WO9951625 A3 WO 9951625A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
screening
protein
peptides
scaffold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/007374
Other languages
French (fr)
Other versions
WO1999051625A9 (en
WO1999051625A2 (en
Inventor
David Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Priority to CA002324284A priority Critical patent/CA2324284A1/en
Priority to JP2000542346A priority patent/JP2002510479A/en
Priority to NZ507063A priority patent/NZ507063A/en
Priority to AU34693/99A priority patent/AU752168B2/en
Priority to EP99916352A priority patent/EP1071705A2/en
Publication of WO1999051625A2 publication Critical patent/WO1999051625A2/en
Publication of WO1999051625A3 publication Critical patent/WO1999051625A3/en
Anticipated expiration legal-status Critical
Publication of WO1999051625A9 publication Critical patent/WO1999051625A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is directed to compositions and methods comprising peptides which have a high affinity for each other and, when linked to a protein, are used to help fold the protein into a compact structure. By virtue of its stability and constraints, this scaffold can prolong the activity of any embedded protein sequences in the presence of cellular and other proteases. The compact structure can have other functional sequences embedded, and is preferable to linear and less constrained peptides for library screening, for creating structurally-biased peptide libraries and for targeting to specific intracellular and extracellular compartments. Compositions of the present invention can be displayed on the surface of viruses, archaebacteria, prokaryotic and eukaryotic cells for library screening, drug screening and display. Methods of the present invention are useful for screening in vivo for intracellular effector proteins modulating signaling pathways and to identify interacting proteins in vitro. Thus, the present invention is useful as a scaffold for gene therapy, for the isolation of new therapeutic drug leads and for potential use as a therapeutic in physiological fluids.
PCT/US1999/007374 1998-04-02 1999-04-02 Peptides causing formation of compact structures Ceased WO1999051625A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002324284A CA2324284A1 (en) 1998-04-02 1999-04-02 Peptides causing formation of compact structures
JP2000542346A JP2002510479A (en) 1998-04-02 1999-04-02 Peptides that cause the formation of compact structures
NZ507063A NZ507063A (en) 1998-04-02 1999-04-02 Self-dimerising peptides causing the formation of compact structures
AU34693/99A AU752168B2 (en) 1998-04-02 1999-04-02 Peptides causing formation of compact structures
EP99916352A EP1071705A2 (en) 1998-04-02 1999-04-02 Peptides causing formation of compact structures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8044498P 1998-04-02 1998-04-02
US60/080,444 1998-04-02

Publications (3)

Publication Number Publication Date
WO1999051625A2 WO1999051625A2 (en) 1999-10-14
WO1999051625A3 true WO1999051625A3 (en) 2000-04-06
WO1999051625A9 WO1999051625A9 (en) 2001-07-05

Family

ID=22157430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007374 Ceased WO1999051625A2 (en) 1998-04-02 1999-04-02 Peptides causing formation of compact structures

Country Status (7)

Country Link
EP (1) EP1071705A2 (en)
JP (1) JP2002510479A (en)
CN (1) CN1302305A (en)
AU (1) AU752168B2 (en)
CA (1) CA2324284A1 (en)
NZ (1) NZ507063A (en)
WO (1) WO1999051625A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493529B2 (en) 2010-04-14 2016-11-15 Sanofi Robo1-Fc fusion protein and use thereof for treating tumours

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189934A2 (en) * 1999-05-14 2002-03-27 Medical Research Council Oligomeric chaperone proteins
ATE296350T1 (en) 1999-06-14 2005-06-15 Genentech Inc STRUCTURED PEPTIDE SCAFFOLD FOR DISPLAYING TURNED LIBRARIES ON PHAGE
WO2001030830A2 (en) * 1999-10-26 2001-05-03 Mitokor Gene sequences identified by protein motif database searching
JP4586275B2 (en) * 2001-01-17 2010-11-24 味の素株式会社 Method for identifying the interface of a composite
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
EP2222704A4 (en) 2007-11-27 2011-02-09 Univ British Columbia 14-3-3 ETA ANTIBODIES AND THEIR USES FOR THE DIAGNOSIS AND TREATMENT OF ARTHRITIS
JP5658866B2 (en) * 2009-04-23 2015-01-28 花王株式会社 Evaluation method
EP3027224B1 (en) * 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
IL288147B2 (en) * 2014-05-21 2024-03-01 Harvard College RAS inhibitory peptides and their uses
CN105399802B (en) * 2015-12-08 2020-04-03 中国农业科学院兰州兽医研究所 Type A foot-and-mouth disease genetically engineered compound epitope protein and vaccine
CN105777909B (en) * 2016-03-03 2020-04-03 中国农业科学院兰州兽医研究所 A porcine chemokine-mediated targeting complex epitope protein and vaccine for type A foot-and-mouth disease
CN106220740A (en) * 2016-08-18 2016-12-14 中山大学 Soluble protein BAFF is in B cell In vitro culture and the application of amplification
CN108866635B (en) 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 Multispecific protein medicine and library thereof, and preparation method and application thereof
CN109414483B (en) * 2017-05-10 2025-10-24 制药五有限责任公司 Enveloped viruses resistant to complement inactivation for cancer therapy
CN108864276B (en) * 2017-05-16 2023-02-03 上海恒润达生生物科技股份有限公司 NY-ESO-1-targeted T cell receptor combined expression PD 1antibody variable region and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028173A1 (en) * 1993-05-24 1994-12-08 Affymax Technologies N.V. Association peptides
WO1994029332A1 (en) * 1993-06-11 1994-12-22 Smithkline Beecham Corporation Coiled-coil stem loop templates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028173A1 (en) * 1993-05-24 1994-12-08 Affymax Technologies N.V. Association peptides
WO1994029332A1 (en) * 1993-06-11 1994-12-22 Smithkline Beecham Corporation Coiled-coil stem loop templates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UJWAL SHINDE ET AL: "INTRAMOLECULAR CHAPERONES AND PROTEIN FOLDING", TIBS TRENDS IN BIOCHEMICAL SCIENCES,EN,ELSEVIER PUBLICATION, CAMBRIDGE, vol. 18, no. 11, 1 November 1993 (1993-11-01), pages 442 - 446, XP000400285, ISSN: 0968-0004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493529B2 (en) 2010-04-14 2016-11-15 Sanofi Robo1-Fc fusion protein and use thereof for treating tumours

Also Published As

Publication number Publication date
AU752168B2 (en) 2002-09-05
WO1999051625A9 (en) 2001-07-05
JP2002510479A (en) 2002-04-09
AU3469399A (en) 1999-10-25
WO1999051625A2 (en) 1999-10-14
CA2324284A1 (en) 1999-10-14
EP1071705A2 (en) 2001-01-31
CN1302305A (en) 2001-07-04
NZ507063A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
WO1999051625A3 (en) Peptides causing formation of compact structures
Dekker et al. Substrate specificity of the integral membrane protease OmpT determined by spatially addressed peptide libraries
Ke et al. Optimal subsite occupancy and design of a selective inhibitor of urokinase
Jia et al. Function of disintegrin-like/cysteine-rich domains of atrolysin A: inhibition of platelet aggregation by recombinant protein and peptide antagonists
Mi et al. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium
DE60203692D1 (en) LATENCY ASSOCIATED PEPTIDES OF TGF-BETA TO LATE PHARMACEUTICALLY ACTIVE PROTEINS
PL372849A1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
YU8997A (en) Purified protein having serinic proteaze inhibiting activity and pharmaceutical preparation containing them
HUP0203409A2 (en) Interferon gamma conjugates
Hayouka et al. Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein
DK1144454T4 (en) Modified peptides as therapeutic agents
PT910647E (en) Human dnase i hyperactive variants
WO2005040418A3 (en) Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt
WO2001083525A3 (en) Modified peptides, comprising an fc domain, as therapeutic agents
EP2277888A3 (en) Fusion proteins of albumin and erythropoietin
HUP0002381A1 (en) Apolipoprotein a-1 agonist peptide derivatives, complexes thereof and pharmaceutical compositions comprising their
AR008727A1 (en) COMPOSITIONS AND MELTING PROTEINS INCLUDING A POLYPEPTIDE INCLUDING AN IMMUNOGENIC PORTION OF A PROSTATE PROTEIN OR ITS VARIANT, AND USES THEREOF TO PREPARE A MEDICINAL PRODUCT
AU2003231878A1 (en) Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
WO1998033920A3 (en) Tissue factor pathway inhibitor-3
ATE323153T1 (en) SPHINGOSINE KINASE
DK1025236T3 (en) Human checkpoint kinase, HCDS1, preparations and methods
ATE443076T1 (en) PROTEASE TYPE II CLAVEABLE PEPTIDE
EP1452543A3 (en) RGD (ARG-GLY-ASP) coupled to (neuro)peptides
Bánóczi et al. Synthesis of cell-penetrating conjugates of calpain activator peptides
AR020101A1 (en) A PEPTIDE ANTAGONIST OF THE HUMAN UROQUINASE RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING HIM, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND METHODOPARA TO SELECT AN ADEQUATE PEPTIDE ANTAGONIST.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99806463.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 34693/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 507063

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999916352

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2324284

Country of ref document: CA

Ref document number: 2324284

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 542346

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999916352

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/22-22/22; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWG Wipo information: grant in national office

Ref document number: 34693/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999916352

Country of ref document: EP